Rationales and uncertainties for aspirin use in COVID-19: a narrative review.
Hazem A Sayed AhmedEric MerrellMansoura IsmailAnwar I JoudehJeffrey B RileyAhmed ShawkatHanan HabebEdward DarlingReda A GowedaMohamed H ShehataHossam AminGary F NiemanHani AiashPublished in: Family medicine and community health (2021)
The authors recommend a low-dose aspirin regimen for primary prevention of arterial thromboembolism in patients aged 40-70 years who are at high atherosclerotic cardiovascular disease risk, or an intermediate risk with a risk-enhancer and have a low risk of bleeding. Aspirin's protective roles in COVID-19 associated with acute lung injury, vascular thrombosis without previous cardiovascular disease and mortality need further randomised controlled trials to establish causal conclusions.
Keyphrases
- low dose
- cardiovascular disease
- cardiovascular events
- coronavirus disease
- sars cov
- end stage renal disease
- type diabetes
- high dose
- ejection fraction
- chronic kidney disease
- newly diagnosed
- pulmonary embolism
- prognostic factors
- coronary artery disease
- atrial fibrillation
- transcription factor
- patient reported outcomes
- cardiovascular risk factors
- binding protein
- inflammatory response